Concord Biotech Limited (CONCORDBIO.NS)

INR 2147.65

(-1.18%)

Market Cap (In INR)

224.67 Billion

Revenue (In INR)

9.98 Billion

Net Income (In INR)

3.08 Billion

Avg. Volume

250.08 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1322.3-2664.0
PE
-
EPS
-
Beta Value
0.0
ISIN
INE338H01029
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ankur Vaid
Employee Count
-
Website
https://www.concordbiotech.com
Ipo Date
2023-08-18
Details
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. It provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. The company also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment; mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, and micafungin sodium for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.